| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9224602 | Clinics in Dermatology | 2005 | 16 Pages |
Abstract
Although GVHD may convey beneficial graft-versus-leukemia/lymphoma effects, it also entails a significant risk of morbidity and mortality. Patients with mild GVHD need only minimal, if any, immunosuppressive treatment, whereas prognosis of patients with extensive disease or resistant to standard immunosuppressive treatment may be dismal. Early recognition of GVHD followed by prompt therapeutic intervention may prevent the progression to higher-grade disease and improve the outcome for patients receiving hematopoietic SCT.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Erich MD, Amaro MD, Alicia MD, Jesus MD,